Data as of Q4 2025 (Dec 31, 2025)

Artia Global Partners LP

โ€ขCIK: 1937964โ€ขFiling: Q4 2025

**Artia Global Partners LP** manages $581M across a diversified portfolio of 50 positions. The fund exhibits significant concentration in select names, notably maintaining a substantial position in IM8N at $118.7M. Key allocations also include ABVX ($81.0M) and ARGX ($54.4M), suggesting a focus on high-conviction, sector-specific opportunities. This structure highlights a concentrated approach targeting outsized returns within its core holdings.

Total AUM
$573.2M
+ $7.9M in options
QoQ Performance
+0.7%
Positions
48
+ 2 options
Top 10 Concentration
74.7%
Latest Filing
Q4 2025

Top Holdings Allocation

IM8N
ABVX
ARGX
LLY
IM8N20.4%
ABVX13.9%
ARGX9.4%
LLY9.3%
VKTX4.4%
TRVI4.3%
QURE4.2%
NAMS3.0%

๐Ÿ“ˆ Biggest Buys

ABVX
ABIVAX SA
+166.5%
13.9% of portfolio
LLY
ELI LILLY & CO
+76.0%
9.3% of portfolio
VKTX
VIKING THERAPEUTICS INC
+392.1%
4.4% of portfolio
CDTX
CIDARA THERAPEUTICS INC
NEW
2.7% of portfolio
NAMS
NEWAMSTERDAM PHARMA COMPANY
+158.6%
3.0% of portfolio

๐Ÿ“‰ Biggest Sells

SLNOCALL
SOLENO THERAPEUTICS INC
-92.6%
0.4% of portfolio
UGLPUT
PROSHARES TR II
-81.4%
1.0% of portfolio
ARGX
ARGENX SE
-17.4%
9.4% of portfolio
IM8N
INSMED INC
-6.8%
20.4% of portfolio
DGX
QUEST DIAGNOSTICS INC
-50.1%
1.2% of portfolio

Sector Breakdown

Other90.1%
Healthcare9.9%

๐Ÿšช Exited Positionssold since Q3 2025

VRNA
VERONA PHARMA PLC
SOLD
$40.4M
2GH
MERUS N V
SOLD
$27.9M
VRTX
VERTEX PHARMACEUTICALS INC
SOLD
$21.6M
BSX
BOSTON SCIENTIFIC CORP
SOLD
$17.9M
REGN
REGENERON PHARMACEUTICALS
SOLD
$6.0M
+13 more exited positions

Changes from Q3 2025

NEW19 new positions
โ†‘13 increased
โ†“7 decreased

Historical Filings

Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023